U.S., Dec. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07264517) titled 'Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).' on Nov. 24.
Brief Summary: This is a Phase 2, multi-site, double-masked, randomized, vehicle-controlled, study designed to evaluate the safety, tolerability, and efficacy in adult participants with DED.
Study Start Date: Nov. 03
Study Type: INTERVENTIONAL
Condition:
Dry Eye Disease
Intervention:
DRUG: GRF312 5%
Immune Globulin (Human), (GRF312 5% Ophthalmic Solution
OTHER: Placebo Comparator
Vehicle.
Recruitment Status: RECRUITING
Sponsor: Instituto Grifols, S.A.
Published by HT Digital Content Services with permiss...